Treatment with trastuzumab deruxtecan resulted in clinically meaningful efficacy in patients with HER2-positive gastric or gastroesophageal junction cancer following disease progression on or after a trastuzumab-containing regimen.
The FDA has granted a priority review to the biologics license application seeking the approval of zolbetuximab for the first-line treatment of patients with unresectable, locally advanced or metastatic, HER2-negative, gastric or gastroesophageal junction adenocarcinoma whose tumors are Claudin18.2 positive.
Oral presentation for RATIONALE 305 showed improved survival and manageable safety profile for tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer with PD-L1 expression BeiGene
Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021
LUMAKRAS™ (Sotorasib)¹ Overall Survival and Biomarker Subgroup Analyses From Registrational Phase 2 CodeBreaK 100 Trial in KRAS G12C-Mutated Non-Small Cell Lung Cancer
New Data From the Phase 2 FIGHT Trial with Bemarituzumab in Advanced Gastric and Gastroesophageal Junction Cancers
News provided by
Share this article
Share this article
THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ Amgen (NASDAQ: AMGN) today announced that new data from its expanding oncology pipeline and marketed portfolio will be presented during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place virtually from June 4-8, 2021.
Overall survival (OS) data from the Phase 2 CodeBreaK 100 trial of LUMAKRAS™ (sotorasib), a potentially first-in-class KRAS